(Pooja Dubey, Intern Journalist) Brazilian health authority Envisa said on Wednesday that a volunteer has died in a clinical trial of the COVID-19 vaccine developed by AstraZeneca and the University of Oxford. However, he was not given the dose of this vaccine. In addition, Envisa also said that the vaccine would continue to be tested.
The volunteer who died had been given the Covid-19 vaccine, the trial would have been suspended. They reported that the person was part of the control group that was given the drug for meningitis.
Oxford has confirmed plans to continue these tests. Oxford issued a statement saying that after careful evaluation “there is nothing to worry about the safety of the diagnostic test.”AstraZeneca declined to comment immediately on the matter.
The Covid-19 vaccine being developed by AstraZeneca and the University of Oxford is leading in the race to develop the vaccine. India’s hopes including the world are set on this vaccine. This vaccine is being produced at the Serum Institute in Pune, India.
The Federal University of São Paulo, which is helping coordinate Phase III clinical trials in Brazil, said an independent review committee had also recommended the continuation of the trial. The university previously confirmed Volunteer was Brazilian, but no further personal information was provided about him.
“Everything is proceeding as expected, without any cases of serious vaccine-related complications in any participating volunteer,” the University of Brazil said in a statement.
A university spokesman said that out of 10,000 volunteers involved in the trial, 8,000 have been given the first dose in six Brazilian cities, and many of them have been given the second dose.
According to the latest update from John Hopkins University, there have been 5,273,954 cases of Covid-19 in Brazil and 154,837 people have died so far from this deadly disease.
Covid-19 has caused the most deaths in Brazil after the US. Brazil is the third most affected country in the world after Coronavirus after the US and India.
About Post Author
